Deccan Health Care Ltd

Deccan Health Care Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 08 July 2026, providing investors with an up-to-date view of the company’s performance and outlook.

Deccan Health Care Ltd is rated 'Sell' by MarketsMOJO, with this rating last updated on 18 May 2026. However, the analysis and financial metrics discussed here reflect the stock's current position as of 19 June 2026, providing investors with the most up-to-date insight into the company’s performance and outlook.

Deccan Health Care Ltd has witnessed a significant shift in its valuation parameters, moving from an attractive to a very attractive price range, driven by a marked decline in its price-to-earnings and price-to-book value ratios. This repositioning comes amid a challenging market backdrop and a micro-cap status that continues to weigh on investor sentiment despite recent positive price movements.

Deccan Health Care Limited, a micro-cap healthcare products company specialising in nutraceutical, cosmeceutical and ayurveda products, reported a challenging Q4 FY26 with net profit declining 67.00% quarter-on-quarter to ₹0.33 crores despite revenue growing 20.64% to ₹20.98 crores. The ₹32.00 crore market capitalisation company saw its stock trade at ₹12.80, down 43.36% over the past year and significantly underperforming both the Sensex and its healthcare services sector peers.

Deccan Health Care Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 18 May 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The healthcare services micro-cap, with a current market price of ₹12.33, continues to underperform the broader market but shows signs of stabilisation in its technical trend, prompting a reassessment of its outlook.

Deccan Health Care Ltd has seen its investment rating downgraded from Sell to Strong Sell as of 12 May 2026, reflecting deteriorating technical indicators and persistent fundamental weaknesses. Despite some positive quarterly financial results and rising promoter confidence, the stock’s overall outlook has worsened due to bearish technical trends, underwhelming long-term returns, and valuation concerns within the healthcare services sector.

Deccan Health Care Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 29 Apr 2026, driven primarily by a shift in technical indicators despite persistent fundamental challenges. The healthcare services micro-cap, with a market capitalisation classified as micro-cap and a current Mojo Score of 34.0, has demonstrated mixed signals across quality, valuation, financial trends, and technical parameters, prompting a nuanced reassessment by analysts.

Deccan Health Care Ltd, a micro-cap player in the Healthcare Services sector, has seen its investment rating downgraded from Sell to Strong Sell as of 23 April 2026. This revision reflects deteriorating technical indicators, persistent underperformance against benchmarks, and weak long-term fundamental metrics despite some recent positive financial results and rising promoter confidence.

Deccan Health Care Ltd, a micro-cap player in the healthcare services sector, has seen its investment rating upgraded from Strong Sell to Sell as of 15 Apr 2026. This change reflects a nuanced shift in the company’s technical outlook amid persistent fundamental challenges and valuation considerations. The upgrade is primarily driven by improvements in technical indicators, while financial trends and quality metrics continue to weigh on the stock’s prospects.

Deccan Health Care Ltd has seen its investment rating upgraded from Sell to Strong Sell as of 7 April 2026, driven primarily by an improved valuation profile despite ongoing challenges in financial performance and technical indicators. The healthcare services micro-cap, with a current Mojo Score of 29.0, now presents an attractive valuation but continues to struggle with weak long-term fundamentals and underwhelming returns relative to the broader market.

Deccan Health Care Ltd has witnessed a notable shift in its valuation parameters, moving from a very attractive to an attractive rating, despite ongoing operational challenges and a micro-cap status. With a current price of ₹9.97 and a significant day gain of 9.92%, the healthcare services company’s price-to-earnings (P/E) and price-to-book value (P/BV) ratios suggest a compelling entry point relative to its peers and historical benchmarks.

For the tenth consecutive session, Deccan Health Care Ltd has closed lower, culminating in a fresh 52-week low of Rs 6.65 on 30 Mar 2026. This relentless decline has wiped out 44.39% of value in just over a week, signalling sustained selling pressure despite some positive financial indicators.

Despite a broadly positive market environment, Deccan Health Care Ltd has continued its downward trajectory, hitting an all-time low of ₹7.48 on 30 Mar 2026 after a prolonged period of decline.

For the ninth consecutive session, Deccan Health Care Ltd has closed lower, culminating in a fresh 52-week low of Rs 7.57 on 27 Mar 2026. This extended decline has wiped out over 38% of the stock’s value in just over a week, underscoring persistent selling pressure despite some positive financial indicators.